Cargando…

Combination of Rapamycin and MK-2206 Induced Cell Death via Autophagy and Necroptosis in MYCN-Amplified Neuroblastoma Cell Lines

Neuroblastoma (NB) is the most common pediatric malignant extracranial solid tumor. Despite multi-modality therapies, the emergence of drug resistance is an obstacle in the treatment of high-risk NB patients (with MYCN amplification). In our previous study, we found that rapamycin and MK-2206 synerg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Yudi, Gong, Wei, Hua, Zhongyan, Chen, Bo, Zhao, Guifeng, Liu, Zhihui, Thiele, Carol J., Li, Zhijie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033642/ https://www.ncbi.nlm.nih.gov/pubmed/32116708 http://dx.doi.org/10.3389/fphar.2020.00031

Ejemplares similares

Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells
por: Gong, Baocheng, et al.
Publicado: (2021)

Corrigendum: Downregulation of ATXN3 enhances the sensitivity to AKT inhibitors (Perifosine or MK-2206), but decreases the sensitivity to chemotherapeutic drugs (etoposide or cisplatin) in neuroblastoma cells
por: Gong, Baocheng, et al.
Publicado: (2022)

MYCN is amplified during S phase, and c-myb is involved in controlling MYCN expression and amplification in MYCN-amplified neuroblastoma cell lines
por: Aygun, Nevim, et al.
Publicado: (2019)

The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK
por: Wang, Jing, et al.
Publicado: (2018)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
por: Qi, Lei, et al.
Publicado: (2015)

Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells
por: Wang, Jing, et al.
Publicado: (2014)

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma
por: Misiak, Danny, et al.
Publicado: (2021)

Multi-omic profiling of MYCN-amplified neuroblastoma cell-lines
por: Dassi, Erik, et al.
Publicado: (2015)

Elimination of MYCN-Amplified Neuroblastoma Cells by Telomerase-Targeted Oncolytic Virus via MYCN Suppression
por: Tanimoto, Terutaka, et al.
Publicado: (2020)

MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma
por: Floros, Konstantinos V., et al.
Publicado: (2022)

Erratum to: PDK1-mTOR signaling pathway inhibitors reduce cell proliferation in MK2206 resistant neuroblastoma cells
por: Qi, Lei, et al.
Publicado: (2015)

MYCN-amplified neuroblastoma cell-derived exosomal miR-17-5p promotes proliferation and migration of non-MYCN amplified cells
por: Chen, Weiming, et al.
Publicado: (2021)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma
por: Zhang, Hai-Feng, et al.
Publicado: (2023)

PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma
por: Hua, Zhongyan, et al.
Publicado: (2016)

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma
por: Lee, Eunjin, et al.
Publicado: (2020)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells
por: Murakami-Tonami, Yuko, et al.
Publicado: (2016)

Targeting condensin, a vital spot of MYCN-amplified neuroblastoma
por: Tanno, Yuji, et al.
Publicado: (2014)

Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma
por: Hald, Øyvind H., et al.
Publicado: (2018)

CAMKV Is a Candidate Immunotherapeutic Target in MYCN Amplified Neuroblastoma
por: Sussman, Robyn T., et al.
Publicado: (2020)

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells
por: Malkomes, Patrizia, et al.
Publicado: (2016)

Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells
por: Djuzenova, Cholpon S., et al.
Publicado: (2019)

FOXR2 Stabilizes MYCN Protein and Identifies Non–MYCN-Amplified Neuroblastoma Patients With Unfavorable Outcome
por: Schmitt-Hoffner, Felix, et al.
Publicado: (2021)

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma
por: Tan, Kezhe, et al.
Publicado: (2022)

Proteome and Acetylome Analysis Identifies Novel Pathways and Targets Regulated by Perifosine in Neuroblastoma
por: Gu, Xiao, et al.
Publicado: (2017)

Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line
por: López-Carrasco, Amparo, et al.
Publicado: (2020)

Exploitation of chick embryo environments to reprogram MYCN-amplified neuroblastoma cells to a benign phenotype, lacking detectable MYCN expression
por: Carter, R, et al.
Publicado: (2012)

Single-Cell Gene Network Analysis and Transcriptional Landscape of MYCN-Amplified Neuroblastoma Cell Lines
por: Mercatelli, Daniele, et al.
Publicado: (2021)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

Gene expression and molecular pathway activation signatures of MYCN-amplified neuroblastomas
por: Petrov, Ivan, et al.
Publicado: (2017)

Serine–glycine-one-carbon metabolism: vulnerabilities in MYCN-amplified neuroblastoma
por: Zhao, Erhu, et al.
Publicado: (2020)

EP300 Selectively Controls the Enhancer Landscape of MYCN-Amplified Neuroblastoma
por: Durbin, Adam D., et al.
Publicado: (2022)

Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy
por: Valind, Anders, et al.
Publicado: (2023)

The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma
por: Wang, Donghai, et al.
Publicado: (2023)

MYCN and the epigenome
por: He, Stanley, et al.
Publicado: (2013)

MYCN mRNA degradation and cancer suppression by a selective small-molecule inhibitor in MYCN-amplified neuroblastoma
por: Liu, Tao, et al.
Publicado: (2022)

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma
por: Stover, Elizabeth H., et al.
Publicado: (2022)

Antitumor effects of the small molecule DMAMCL in neuroblastoma via suppressing aerobic glycolysis and targeting PFKL
por: Zhang, Simeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1s1evv8c6gtb1oq7ob1ahuj63o